We had an in-depth interview with Tim Moore, CEO of HAVN Life Sciences (CSE:HAVN) (OTC: HAVLF). He gave us an overview of their strategic positioning in the Psychedelic Market, and discussed the supply agreement within their distribution network. Tim also explained the regulatory challenges of working with psilocybin and the market potential of functional mushrooms.
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.